曲美他嗪对慢性心力衰竭患者心功能的影响

目的观察曲美他嗪(trimetazidine,TMZ)对慢性心力衰竭(chronicheartfailure,CHF)患者心功能的影响,并探讨其机制。方法选取60例CHF患者,随机分为对照组(n=30,常规抗心衰治疗)和TMZ组(n=30,在常规抗心衰治疗的基础上加用TMZ,20mg/d,3次/d)。观察期限为6个月。全部入选病人在用药前和用药6个月时行超声心动图检查,用左心室收缩末期内径(LVEDs)、舒张末期内径(LVEDd)、左心室射血分数(LVEF)和心功能(NYHA分级)评价心功能转归。结果用药6个月后,TMZ组LVEF较治疗前明显增加[(42·6±3·9)%vs(32·3±1·7)%](P<0·001),也明显高于对照组治疗后水平[(42·6±3·9)%vs(35·9±2·8)%](P<0·001)。两组LVEDd、LVEDs治疗6个月后均较治疗前明显缩小(P<0·05)。但在治疗前和治疗后两组间LVEDd、LVEDs、心功能NYHA分级之间差异无显著性意义(P>0·05)。结论在常规抗心衰治疗的基础上加用TMZ可以明显改善CHF患者的心功能。

Effect of trimetazidine on cardiac function in patients with chronic heart failure

Objective To observe the effect of trimetazidine(TMZ) on cardiac function in patients with chronic heart failure (CHF). Methods Sixty patients with CHF were randomly divided into control group and TMZ group. The observing period was 6 months. The echocardiography was performed before and after evaluation of cardiac function. Results The result showed that the LVEF was significantly increased in TMZ group(P<0.001). Conclusion TMZ can improve the cardiac function in patients with CHF on the basis of routine therapy.